Best of ASCO - 2014 Annual Meeting



Attend this session at the
2019 ASCO Annual Meeting!

Session: Breast Cancer—Local/Regional/Adjuvant

Type: Poster Session

Time: Sunday June 2, 8:00 AM to 11:00 AM

Location: Hall A

Session: Breast Cancer—Local/Regional/Adjuvant

Type: Poster Discussion Session

Time: Sunday June 2, 4:30 PM to 6:00 PM

Location: Hall D2

Low-fat dietary pattern and long-term breast cancer incidence and mortality: The Women’s Health Initiative randomized clinical trial.

Neoadjuvant Therapy

Breast Cancer—Local/Regional/Adjuvant

2019 ASCO Annual Meeting

Abstract No:

Poster Board Number:
Poster Discussion Session (Board #12)

J Clin Oncol 37, 2019 (suppl; abstr 520)

Author(s): Rowan T. Chlebowski, Aaron K Aragaki, Garnet L Anderson, Kathy Pan, Marian L Neuhouser, JoAnn E Manson, Cynthia A. Thomson, Yasmin Mossavar-Rahmani, Dorothy Lane, Karen Johnson, Jean Wactawski-Wende, Snetselaar Linda, Thomas E Rohan, Juhua Luo, Ana Barac, Ross L Prentice; Los Angeles BioMedical Research Institute, Torrance, CA; Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; Brigham and Women's Hospital/Harvard Medical School, Boston, MA; University of Arizona, Tucson, AZ; Albert Einstein College of Medicine, Bronx, NY; State University of New York at Stony Brook, Stony Brook, NY; University of Tennessee Health Science Center, Memphis, TN; University of Buffalo, Buffalo, NY; University of Iowa, Bloomington, IN; University of Indiana, Bloomington, IN; MedStar Heart and Vascular Institute, Washington, DC

Abstract Disclosures


Background: Observational studies of dietary fat intake and breast cancer have inconsistent findings. To address this issue, the Women’s Health Initiative (WHI) Dietary Modification (DM) clinical trial assessed a low-fat dietary pattern influence on breast cancer incidence and outcome. Methods: The WHI DM trial is a randomized, controlled clinical trial conducted at 40 US centers, where 48,835 postmenopausal women, aged 50-79 years, with no previous breast cancer and dietary fat intake ≥32% of total energy, were randomly assigned, from 1993-1998, to a usual diet comparison group (60%) or dietary intervention group (40%) with goals to reduce fat intake to 20% of energy and increase vegetables, fruit, and grain intake. This study is registered as: NCT00000611. Results: The dietary intervention significantly reduced fat intake; increased fruit, vegetable and grain intake with modest weight loss (3%) (all P< 0.001). During 8.5 years of dietary intervention, there were 8% fewer breast cancers and deaths from breast cancer were somewhat lower in the intervention group but the rates were not significantly different. However, deaths after breast cancer (breast cancer followed by death from any cause) were significantly reduced in the intervention group, both during intervention (hazard ratio [HR] 0·65 95% confidence interval [CI] 0·45-0·95) and through 16.1 year (median) cumulative follow-up. Now, after long- term, cumulative 19.6 year (median) follow-up, with 3,374 incident breast cancers, the significant reduction in deaths after breast cancer continued (with 1,011 deaths, HR 0·85 95% CI 0·74-0·96) and a significant reduction in deaths from breast cancer (breast cancer followed by death attributed to the breast cancer) emerged (with 383 deaths, HR 0·79 95% CI 0·64-0·97). Conclusions: Adoption of a low-fat dietary pattern associated with increased vegetable, fruit, and grain intake, demonstrably achievable by many, significantly reduced the risk of death from breast cancer in postmenopausal women. To our review, these findings provide the first randomized clinical trial evidence that a dietary change can reduce a postmenopausal woman’s risk of dying from breast cancer. Clinical trial information: NCT00000611

Other Abstracts in this Sub-Category:


1. Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer: Results from the Swedish PREDIX HER2 trial identifying a new potential de-escalation standard?

Meeting: 2019 ASCO Annual Meeting Abstract No: 501 First Author: Jonas C. S. Bergh
Category: Breast Cancer—Local/Regional/Adjuvant - Neoadjuvant Therapy


2. GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (HRD).

Meeting: 2019 ASCO Annual Meeting Abstract No: 506 First Author: Peter A. Fasching
Category: Breast Cancer—Local/Regional/Adjuvant - Neoadjuvant Therapy


3. TBCRC 030: A randomized phase II study of preoperative cisplatin versus paclitaxel in TNBC—Evaluating the homologous recombination deficiency (HRD) biomarker.

Meeting: 2019 ASCO Annual Meeting Abstract No: 507 First Author: Erica L. Mayer
Category: Breast Cancer—Local/Regional/Adjuvant - Neoadjuvant Therapy